Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527603 | 0.83 | TDP1 (0.42) | RIPK1GAA | |
| SCHEMBL7430459 | 0.77 | RIPK1 (0.59) | KDM1AHDAC8HDAC6RIPK1KCNQ4 | |
| SCHEMBL17553442 | 0.76 | RIPK1 (0.47) | KDM1AHDAC8HDAC6RIPK1KCNQ4 | |
| SCHEMBL4762254 | 0.73 | GRM2 (0.48) | KDM1AHDAC8HDAC6RIPK1KCNQ4 | |
| SCHEMBL4767513 | 0.73 | GRM2 (0.54) | KDM1AHDAC8HDAC6RIPK1KCNQ4 | |
| SCHEMBL2892096 | 0.73 | HDAC3 (0.45) | KDM1AHDAC8HDAC6RIPK1KCNQ4 | |
| SCHEMBL28706862 | 0.73 | KDM1A (0.42) | KDM1AHDAC8HDAC6RIPK1KCNQ4 | |
| SCHEMBL7702197 | 0.72 | RIPK1 (0.43) | KDM1AHDAC8HDAC6RIPK1KCNQ4 | |
| SCHEMBL2528423 | 0.72 | RIPK1 (0.47) | KDM1AHDAC8HDAC6RIPK1KCNQ4 | |
| SCHEMBL18763349 | 0.72 | RIPK1 (0.43) | KDM1AHDAC8HDAC6RIPK1KCNQ4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7491819-B1 | N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1948666-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007064619-A1 | PYRIMIDINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064316-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129379-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-07 | — | — | US | disclosed |
| WO-2007061714-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129379-A1 | HIV INTEGRASE INHIBITORS | TYMP, POLN, IMPDH1 | KDM1A 357/4885HDAC8 994/4885HDAC6 3753/4885 |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | KDM1A 549/4885HDAC8 615/4885HDAC6 2911/4885 |
| US-20070111984-A1 | HIV integrase inhibitors | TYMP, POLN, IMPDH1 | KDM1A 357/4885HDAC8 994/4885HDAC6 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.